Research programme: janus kinase inhibitors- Rigel Pharmaceuticals

Drug Profile

Research programme: janus kinase inhibitors- Rigel Pharmaceuticals

Alternative Names: A 301; ATI 50002

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Aclaris Therapeutics; Rigel Pharmaceuticals
  • Class
  • Mechanism of Action Janus kinase inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alopecia areata; Vitiligo
  • Discontinued Haematological malignancies

Most Recent Events

  • 08 Aug 2017 Aclaris Therapeutics plans to initiate a phase II trial of of ATI-50002 for Vitiligo in USA in the second half of 2017
  • 08 Aug 2017 Aclaris Therapeutics plans two phase II trials of ATI-50002 for Alopecia areata in USA in the second half of 2017
  • 03 Aug 2017 Aclaris Therapeutics files an IND application with the US FDA for Alopecia areata
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top